Market Research Reports

Epigenetics Drugs and Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018

112pages
Published Date: 2013-06-26
 

Description



Epigenetics is a regulatory mechanism that controls the gene expression without altering the genetic sequence. Epigenetic change in gene expression originates from the modification in transcription mechanism. Key components involved in the process of epigenetic transcriptory regulation include DNA methylation, histone modifications, micro RNA’s and non-coding RNA’s. However, our report focuses majorly on two types of epigenetic control factors: DNA methylation and covalent modification in histone proteins around which the DNA helix is wrapped. Epigenetic drugs make it possible to reverse the aberrant gene expression which leads to various disease states. With the increase in aging population, rising incidence of oncology and non-oncology disorders, the demand for epigenetic diagnosis and drugs would also increase.

The research report on Epigenetics Drugs and Diagnostic Technologies market provides detailed analysis of the global market and helps in understanding the driving forces for the growth of these technologies. The report on epigenetics drugs and diagnostic technologies has been categorized based on the mechanism of action which includes DNMT inhibitors and HDAC inhibitors. The segment of the report also provides market and forecast of blockbuster drugs such as vorinostat, romidepsin, azacitidine and decitabine. Furthermore, the report on epigenetics is also categorized based on diagnostic technologies namely DNA Methylation and ChIP (Chromatin Immunoprecipitation) Technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each of the segment and its sub-segment, in terms of USD million, using 2010 as a base year. The epigenetics drugs and diagnostic technologies market report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2012 to 2018. 

Geographically, the epigenetics drugs and diagnostics technologies market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019, along with the CAGR (%) for the forecast period 2013 to 2019. The epigenetics drugs and diagnostics technologies market study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises a qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five forces analysis and market attractiveness analysis. The entire section of market overview plays an important role in understanding the market on a global level. Separately, executive summary has been provided in the report, gives a brief overview of the report in a very precise and concise manner.

The epigenetics drugs and diagnostic technologies market report also provides a highlight of the competitive landscape of the market wherein the market share analysis of the leading players, in terms of percentage share in 2011 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares.

The report concludes with the profiles of the major players in epigenetics drugs and diagnostic technologies market. Market players are profiled based on attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits, product portfolio and recent developments. Key market player’s profiles in this report are Celenge, Eisai Pharmaceuticals, Pharmacyclics, Merck, 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Chroma Therapeutics Ltd., Epigentek Group Inc., EnVivo Pharmaceuticals Inc., Epizyme, Inc. Illumina Inc., Merck & Company Inc., MDxHealth, Oncolys BioPharma Inc., Novartis International AG, Promega Corporation, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Inc. Topotarget A/S, Valirx Plc and others.

The global epigenetics drugs and diagnostic technologies market is segmented into the following categories:
  • Epigenetics Drugs Market, by Mechanism of Action
    • DNMT Inhibitors
      • Azacitidine (Vidaza)
      • Decitabine (Dacogen)
    • HDAC Inhibitors
      • Vorinostat (Zolinza)
      • Romidepsin (Istodax)
  • Epigenetics Diagnostic Technologies Market, by Types
    • DNA Methylation
    • Chromatin Immunoprecipitation (ChIP) Technology
  • Epigenetics Technologies Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • RoW

Table of Contents


Table of Content

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Epigenetics Market (2011 & 2018)
2.2 Global Epigenetics Market, by Segments, 2011 (USD Million)

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
      3.2.1 Increase in Demand for the Treatment of Oncology and Non-Oncology Conditions
      3.2.2 Huge Amounts of Investment
      3.2.3 Advances in Screening Tools
      3.2.4 Impact Analysis of Market Drivers
3.3 Market Restraints
      3.3.1 Genericization of Major Drugs
      3.3.2 Impact Analysis of Market Restraints
3.4 Market Opportunities
3.5 Porter’s Five Forces Analysis
      3.5.1 Bargaining Power of Buyers
      3.5.2 Bargaining Power of Suppliers
      3.5.3 Threat of New Entrants
      3.5.4 Threat of Substitutes
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis

Chapter 4 Epigenetics Drugs Market, By Mechanism Of Action
4.1 Overview
      4.1.1 Global Epigenetic Drugs Market, By Mechanism Of Action, 2010 – 2018 (USD Million)
      4.1.2 Histone Deacetylase (HDAC) Inhibitors
      4.1.3 Global HDAC Inhibitors Market, By Drugs, 2010 – 2018 (USD Million)
              4.1.3.1 Vorinostat
              4.1.3.2 Global Vorinostat Market, By Types 2010 – 2018 (USD Million)
              4.1.3.3 Romidepsin
              4.1.3.4 Global Romidepsin Market, By Types 2010 – 2018 (USD Million)
      4.1.4 DNA Methyltransferase (DNMT) Inhibitors
      4.1.5 Global DNMT Inhibitors Market, By Drugs, 2010–2018 (USD Million)
              4.1.5.1 Decitabine
              4.1.5.2 Global Decitabine Market, By Types 2010 – 2018 (USD Million)
              4.1.5.3 Azacitidine
              4.1.5.4 Global Azacitidine Market, By Types 2010 – 2018 (USD Million)
      4.1.6 Pipeline Drugs
               4.1.6.1 Mocetinostat
               4.1.6.2 Abexinostat
               4.1.6.3 Resminostat
               4.1.6.4 Rocilinostat
               4.1.6.5 CHR 3996
               4.1.6.6 EVP 0334
               4.1.6.7 Panobinostat
               4.1.6.8 Belinostat
               4.1.6.9 Entinostat
               4.1.6.10 Valproic Acid
               4.1.6.11 Histone Methyltransferase (HMT) Inhibitors

Chapter 5 Epigenetics Diagnostic Technology Market, By Types
5.1 Overview
       5.1.1 Global Epigenetic Diagnostic Technologies Market, By Types, 2010 – 2018 (USD Million)
5.2 DNA Methylation
               5.2.1.1 Global DNA Methylation Technology Market, By Types 2010 – 2018 (USD Million)
      5.2.2 Chromatin Immunoprecipitation (Chip)
               5.2.2.1 Global Chromatin Immunoprecipitation (Chip) Technology Market, By Types 2010 – 2018 (USD Million)

Chapter 6 Global Epigenetics Technologies Market, By Geography
6.1 Overview
       6.1.1 Global Epigenetics Technologies Market, By Geography, 2010–2018 (USD Million)
6.2 Comparative Analysis: Epigenetic Technologies Market, By Geography, 2011 & 2018 (Value %)
6.3 North America
       6.3.1 North America Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
6.4 Europe
       6.4.1 Europe Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
6.5 Asia-Pacific
       6.5.1 Asia-Pacific Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
6.6 Rest of the World
       6.6.1 Row Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis, By Key Players (%)

Chapter 8 Recommendations
8.1 Market Strategy for Success
8.2 Barriers to be Considered

Chapter 9 Company Profiles
9.1 4SC AG
       9.1.1 Company Overview
       9.1.2 Financial Overview
       9.1.3 Product Overview
       9.1.4 Business Strategy
       9.1.5 Recent Developments
9.2 Acetylon Pharmaceuticals, Inc.
       9.2.1 Company Overview
       9.2.2 Financial Overview
       9.2.3 Product Overview
       9.2.4 Business Strategy
       9.2.5 Recent Developments
9.3 Astex Pharmaceuticals Inc.
       9.3.1 Company Overview
       9.3.2 Financial Overview
       9.3.3 Product Portfolio
       9.3.4 Business Strategy
       9.3.5 Recent Developments
9.4 Cellcentric Ltd.
       9.4.1 Company Overview
       9.4.2 Financial Overview
       9.4.3 Product Portfolio
       9.4.4 Business Strategy
       9.4.5 Recent Developments
9.5 Celleron Therapeutics Ltd.
       9.5.1 Company Overview
       9.5.2 Financial Overview
       9.5.3 Product Portfolio
       9.5.4 Business Strategy
9.6 Celgene Corporation
       9.6.1 Business Overview
       9.6.2 Financial Overview
       9.6.3 Business Strategy
       9.6.4 Recent Developments
9.7 Chroma Therapeutics Ltd.
       9.7.1 Company Overview
       9.7.2 Financial Overview
       9.7.3 Product Overview
       9.7.4 Business Strategy
       9.7.5 Recent Developments
9.8 Epigentek Group Inc.
       9.8.1 Business Overview
       9.8.2 Financial Overview
       9.8.3 Business Strategy
       9.8.4 Recent Developments
9.9 Eisai Co. Ltd.
       9.9.1 Company Overview
       9.9.2 Financial Overview
       9.9.3 Product Portfolio
       9.9.4 Business Strategy
       9.9.5 Recent Developments
9.10 Envivo Pharmaceuticals Inc.
       9.10.1 Company Overview
       9.10.2 Financial Overview
       9.10.3 Product Portfolio
       9.10.4 Business Strategy
9.11 Epizyme, Inc.
       9.11.1 Company Overview
       9.11.2 Financial Overview
       9.11.3 Product Portfolio
       9.11.4 Business Strategy
       9.11.5 Recent Developments
9.12 Illumina Inc.
       9.12.1 Company Overview
       9.12.2 Financial Overview
       9.12.3 Product Portfolio
       9.12.4 Business Strategies
       9.12.5 Recent Developments
9.13 Mdxhealth
       9.13.1 Company Overview
       9.13.2 Financial Overview
       9.13.3 Product Portfolio
       9.13.4 Business Strategy
       9.13.5 Recent Developments
9.14 Merck & Company Inc.
       9.14.1 Company Overview
       9.14.2 Financial Overview
       9.14.3 Product Portfolio
       9.14.4 Business Strategy
9.15 Novartis International AG
       9.15.1 Company Overview
       9.15.2 Financial Overview
       9.15.3 Product Portfolio
       9.15.4 Business Strategy
       9.15.5 Mergers And Acquisitions
9.16 Oncolys Biopharma Inc.
       9.16.1 Company Overview
       9.16.2 Financial Overview
       9.16.3 Product Portfolio
       9.16.4 Business Strategy
9.17 Pharmacyclics, Inc.
       9.17.1 Company Overview
       9.17.2 Financial Overview
       9.17.3 Product Portfolio
       9.17.4 Business Strategy
       9.17.5 Recent Developments
9.18 Promega Corporation
       9.18.1 Company Overview
       9.18.2 Financial Overview
       9.18.3 Product Portfolio
       9.18.4 Business Strategy
       9.18.5 Recent Developments
9.19 Repligen Corporation
       9.19.1 Company Overview
       9.19.2 Financial Overview
       9.19.3 Product Portfolio
       9.19.4 Business Strategy
       9.19.5 Recent Developments
9.20 Spectrum Pharmaceuticals
       9.20.1 Company Overview
       9.20.2 Financial Overview
       9.20.3 Product Portfolio
       9.20.4 Business Strategy
       9.20.5 Recent Developments
9.21 Syndax Pharmaceuticals, Inc.
       9.21.1 Company Overview
       9.21.2 Financial Overview
       9.21.3 Product Portfolio
       9.21.4 Business Strategy
       9.21.5 Recent Developments
9.22 Topotarget A/S
       9.22.1 Company Overview
       9.22.2 Financial Overview
       9.22.3 Product Portfolio
       9.22.4 Business Strategy
       9.22.5 Recent Developments
9.23 Valirx Plc
       9.23.1 Company Profile
       9.23.2 Financial Overview
       9.23.3 Product Portfolio And Technology
       9.23.4 Business Strategy
       9.23.5 Recent Developments

List of Figures

FIG. 1 Epigenetics Technologies: Market Segmentation
FIG. 2 Global Epigenetics Market, By Segments, 2011 (USD Million)
FIG. 3 Evolution in Epigenetics
FIG. 4 Porter’s Five Forces Analysis: Global Epigenetics Drugs and Diagnostic Technologies Market
FIG. 5 Market Attractiveness Analysis: Global Epigenetics Technologies Market, by Geography
FIG. 6 Global Vorinostat Market, 2010 – 2018 (USD Million)
FIG. 7 Global Romidepsin Market, 2010 – 2018 (USD Million)
FIG. 8 Global Decitabine Market, 2010 – 2018 (USD Million)
FIG. 9 Global Azacitidine Market, 2010 – 2018 (USD Million)
FIG. 10 Global DNA Methylation Technology Market, 2010 – 2018 (USD Million)
FIG. 11 Global Chromatin Immunoprecipitation (Chip) Technology Market, 2010 – 2018 (USD Million)
FIG. 12 Comparative Analysis: Epigenetic Technologies Market, By Geography, 2011 & 2018 (Value %)
FIG. 13 Epigenetics Drugs: Market Share, by Key Players, 2011 (%)
FIG. 14 Epigenetics Diagnostics Technologies: Market Share, by Key Players, 2011 (%)
FIG. 15 4SC AG, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 16 Astex Pharmaceuticals, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 17 Celgene Corporation: Annual Revenues, 2010 – 2012 (USD Million)
FIG. 18 Eisai Pharmaceuticals, Annual Revenues: 2010 – 2012 (1 Yen=1.215 USD) (USD Billion)
FIG. 19 Illumina Inc., Annual Sales: 2010 – 2012 (USD Million)
FIG. 20 Mdxhealth, Annual Revenues: 2010 – 2012 (1 Euro = 1.32 USD) (USD Million)
FIG. 21 Merck & Co. Inc., Annual Sales: 2010 – 2012 (USD Billion)
FIG. 22 Novartis International AG., Annual Sales: 2010 – 2012 (USD Million)
FIG. 23 Pharmacyclics, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 24 Repligen, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 25 Spectrum Pharmaceuticals, Annual Revenues: 2010 – 2012 (USD Million)
FIG. 26 Topotarget, Annual Revenues: 2010 – 2012 (1 DKK = 0.175 USD) (USD Million)
FIG. 27 Valirx, Annual Revenues: 2010 – 2012 (1 British Pound = 1.59 USD) (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Epigenetics Market (2011 & 2018)
TABLE 2 Impact Analysis of Market Drivers
TABLE 3 Impact Analysis of Market Restraints
TABLE 4 Global Epigenetic Drugs Market, By Mechanism of Action, 2010 – 2018 (USD Million)
TABLE 5 Global HDAC Inhibitors Market, By Drugs, 2010 – 2018 (USD Million)
TABLE 6 Global DNMT Inhibitors Market, By Drugs, 2010 – 2018 (USD Million)
TABLE 7 Global Epigenetic Diagnostic Technologies Market, By Types, 2010 – 2018 (USD Million)
TABLE 8 Global Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
TABLE 9 North America Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
TABLE 10 Europe Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
TABLE 11 Asia-Pacific Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
TABLE 12 Row Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)

Enquiry Before Buying


Free Market Analysis


Epigenetics is a study of change in the gene expression without any change in gene sequence. With the increase in aging population, and rising incidence of oncology and non-oncology disorders, the demand for epigenetic diagnosis and drugs is also expected to increase. The global epigenetics drugs and diagnostic technologies market was valued at USD 1.6 billion in 2011 and is expected to grow at a CAGR of 19.4% from 2012 – 2018 to reach an estimated value of USD 5.7 billion in 2018. There are several epigenetic drugs developed and in clinical trials for targeting histone deacetylation and DNA methylation enzymes. DNA Methyltransferase (DNMT) and Histone Deacetylase (HDAC) inhibitors are responsible for regulating the cellular expression. Among these two inhibitors, DNMT accounts for a larger share as these inhibitors offer an improved access for targeting cancerous cells. 

The growth of this market is driven by factors such as rising incidence of cancer, advancements in screening tools and huge amounts invested in research and development activities. 

The DNMT inhibitors market holds the major share in the total epigenetics drugs market by mechanism of action. These inhibitors are identified as anticancer agents for inhibiting the activity of DNA methylation. The impact of DNMT inhibitors is highly significant for inhibiting the cell cycle growth. 

North America accounts for the largest share of the epigenetics market. It is expected that North America will dominate around half of the global epigenetics market as all the therapies and technologies are launched first in this region, thus gaining maximum market share in terms of revenue. Oncology and other non-oncology indications (Alzheimer’s and arthritis) are associated with epigenetics. 

There are only four epigenetic drugs available in the market namely, Celgene’s Vidaza and Istodax, Merck’s Zolinza and Eisai Pharmaceuticals’ Dacogen. These three market players accounted for the total epigenetics drugs market, of which Celgene accounted for the largest share of more than 60% in 2011. Two out of four FDA approved drugs are of Celgene; this helps the company to have a lead in the epigenetics drugs market. 

global-epigenetic-drugs-market-by-mechanism-of-action-2010-2018
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research